Buffalo drug development company Athenex Inc. has applied to Chinese regulators for a review of its Oraxol anti-cancer drug.
The Investigational New Drug application to Chinese regulators "reflects our commitment to developing Oraxol as a global anti-cancer drug, as well as our plan to launch clinical studies in China for this product," said Dr. Rudolf Kwan, Athenex's chief medical officer.
Oraxol is an orally administered form of Paclitaxel, which is used to treat breast, ovarian, lung, bladder, prostate, melanoma and esophageal cancer, among others. Athenex currently is conducting a Phase III clinical study on the use of Oraxol to treat breast cancer patients.
The Chinese application is part of Athenex's plan to develop Oraxol for use worldwide, with China being an important part of that development approach, said Jeffery Yordon, Athenex's chief operating officer, in a statement.